Clinical characteristics of Australian treatment-naive patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

Nguyen, J; Wellard, C; Chung, E; Cheah, CY; Dickinson, M; Doo, NW; Keane, C; Talaulikar, D; Berkahn, L; Morgan, S; Hamad, N; Cochrane, T; Johnston, AM; Forsyth, C; Opat, S; Barraclough, A; Mutsando, H; Ratnasingam, S; Giri, P; Wood, EM; McQuilten, ZK; Hawkes, EA; Lymphoma and Related Diseases Registry Investigators

Author(s): Nguyen, J; Wellard, C; Chung, E; Cheah, CY; Dickinson, M; Doo, NW; Keane, C; Talaulikar, D; Berkahn, L; Morgan, S; Hamad, N; Cochrane, T; Johnston, AM; Forsyth, C; Opat, S; Barraclough, A; Mutsando, H; Ratnasingam, S; Giri, P; Wood, EM; McQuilten, ZK; Hawkes, EA; Lymphoma and Related Diseases Registry Investigators;
Details: Publication Year 2023-04,Volume 110,Issue #4,Page 386-395
Journal Title: European Journal of Haematology
Publication Type: Research article
Abstract: Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real-world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first-line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced-stage disease, and 48% of patients with the early-stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients >/=60 years of age with advanced-stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early-stage disease, and 88% in advanced-stage disease. Early progression-free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.
Publisher: Wiley
Keywords: Humans; *Hodgkin Disease; Bleomycin/therapeutic use; Doxorubicin/therapeutic use; Vinblastine/therapeutic use; Dacarbazine/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Australia; Registries; Neoplasm Staging; classical Hodgkin lymphoma; clinical characteristics; demographic; treatment regimen
Department(s): Clinical Haematology
PubMed ID: 36539351
Publisher's Version: https://doi.org/10.1111/ejh.13915
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-08-03 07:58:28

Last Modified: 2023-08-03 08:01:33